Linda Hadous
Gerontology · Detroit, MINPI 1649733965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $992 and has fallen 54.9% since, to $448 in 2025.
Across 79 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$536
- Otsuka America Pharmaceutical, Inc.$431
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$242
- AbbVie$209
- Teva Pharmaceuticals USA, Inc.$147
- Boehringer Ingelheim$125
- plus $717 from 15 others
What the payments were for
- Food & beverage$2,35998%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $536 |
| Otsuka America Pharmaceutical, Inc. | 21 | $431 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $242 |
| AbbVie | 15 | $209 |
| Teva Pharmaceuticals USA, Inc. | 3 | $147 |
| Boehringer Ingelheim | 1 | $125 |
| GSK | 1 | $125 |
| Agios Pharmaceuticals, Inc. | 1 | $104 |
| Novo Nordisk | 1 | $83 |
| Sumitomo Pharma America, Inc. | 6 | $82 |
| Bsn Medical Inc | 1 | $72 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Lilly USA, LLC | 2 | $41 |
| UCB, Inc. | 2 | $33 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $20 |
| Neurelis, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,406 in reported general payments places this provider in the 85th percentile of 279 gerontology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 120 | $69,476 |
| OzempicSemaglutide | 70 | $66,438 |
| MounjaroTirzepatide | 51 | $52,735 |
| TrulicityDulaglutide | 48 | $46,931 |
| JardianceEmpagliflozin | 51 | $37,488 |
| EliquisApixaban | 50 | $31,105 |
| EntrestoSacubitril/Valsartan | 35 | $24,251 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $24,098 |
| Diclofenac Sodium | 42 | $20,054 |
| GemtesaVibegron | 31 | $14,687 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $12,250 |
| XareltoRivaroxaban | 19 | $11,367 |
| Xigduo XrDapaglifloz Propaned/Metformin | 17 | $7,814 |
| DapagliflozinDapagliflozin Propanediol | 16 | $7,320 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 217 | $6,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $41 | $99,66699 claims |
| AstraZenecaFarxiga, Symbicort | $536 | $71,769131 claims |
| Novo NordiskOzempic | $83 | $66,43870 claims |
| Boehringer IngelheimJardiance | $125 | $37,48851 claims |
| PfizerEliquis | $15 | $31,10550 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $125 | $30,29855 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $82 | $14,68731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 279 gerontology providers in Michigan.
Other gerontology in Detroit
- Agnes PileckiDetroit$4K
- Charlene Walton WindhamDetroit$3K
- Gwendolyn WrightGrand Blanc$47K
- Matthew AmanRochester Hills$21K
- Sarah ArnkoffWest Bloomfield$18K
- Deborah GriffinPetoskey$11K
- Angela EmbreeGrand Rapids$10K
- Bethany DalessandroWyandotte$10K
- Gabrielle NadeauJackson$10K
- Cynthera McNeillWest Bloomfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.